However, it is not known whether other important pathways of DNA damage repair operating in cancer cells contribute to and influence the pathologic response in a cisplatin neoadjuvant chemotherapy setting in BRCA1-associated TNBCs. This evidence concerns the gene BRCA1 and cancer.